The popularity of weight loss medications like Ozempic and Wegovy has surged in recent years, offering hope for individuals struggling with obesity and type 2 diabetes. However, emerging research is raising concerns about a potential link between these drugs and a rare form of vision loss. Recent studies suggest a possible increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition affecting the optic nerve that can lead to blindness.
While the absolute risk remains low, the attention surrounding these medications has prompted investigations by regulatory bodies and spurred further research into the potential connection. Understanding the nuances of this potential side effect, and the ongoing efforts to assess the risk, is crucial for both patients and healthcare providers.
What is NAION and How is it Linked to Semaglutide?
NAION occurs when blood flow to the optic nerve is disrupted, leading to sudden, painless vision loss. It’s one of the leading causes of non-traumatic blindness in adults. Researchers have observed an increased incidence of NAION in patients prescribed semaglutide, the active ingredient in both Ozempic and Wegovy. A study published in JAMA Ophthalmology in July 2024, found that individuals with diabetes who were prescribed semaglutide were more than four times more likely to be diagnosed with NAION compared to those with diabetes who did not take the medication. For those with overweight or obesity, the risk was even higher – more than seven times greater.
However, it’s crucial to note that establishing a definitive causal link is complex. The European Medicines Agency (EMA) has identified a safety signal regarding semaglutide and NAION, acknowledging signals from observational studies and meta-analyses, but emphasizing the demand for caution regarding causality. The EMA classifies the risk as “very rare,” meaning it may affect up to 1 in 10,000 treated patients.
Wegovy vs. Ozempic: Is the Risk Different?
Recent reports have indicated a potentially higher risk associated with Wegovy compared to Ozempic. According to Dutch news outlet BNR, patients using Wegovy had a five times greater chance of developing NAION than those using Ozempic. This difference may be related to the higher dosage of semaglutide used in Wegovy, which is specifically approved for weight loss, while Ozempic is primarily prescribed for managing type 2 diabetes.
However, experts caution against drawing firm conclusions at this stage. Joseph Rizzo, MD, a Mass General Brigham ophthalmologist, emphasizes that the findings are preliminary and should not prompt patients to discontinue their medications without consulting their doctor. “To be perfectly clear, I would not take my findings and use them to recommend that patients stop taking their medications,” Dr. Rizzo stated. “Our finding was really the first possible significant negative finding with these drugs.”
Regulatory Response and Ongoing Monitoring
In response to these concerns, regulatory agencies are taking steps to ensure patient safety. The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy® brand. The EMA has mandated that the risk of NAION be included in the product information for Ozempic, Wegovy, and Rybelsus. These updates will be reflected in the drug labels across Europe, providing healthcare professionals and patients with crucial information about the potential side effect.
The ongoing monitoring of these medications and continued research are essential to fully understand the relationship between semaglutide and NAION. Further studies are needed to determine the underlying mechanisms driving this potential association and to identify individuals who may be at higher risk.
As the use of GLP-1 agonists like Ozempic and Wegovy continues to rise – with an 88 percent increase in registered patients in one recent estimate – vigilance and open communication between patients and their healthcare providers are paramount. Individuals experiencing any sudden changes in vision should seek immediate medical attention.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have you or someone you know experienced vision changes while taking Ozempic or Wegovy? Share your thoughts in the comments below.
